0001193125-26-221605
SEC filingImproved operating and net losses reflect R&D discipline from lower acquisition costs and discontinued tildacerfont program, partially offset by TA-ERT ramp-up, though EPS deteriorated sharply post-reverse split while cash burn narrowed.
Since inception, Spruce has incurred significant operating losses and negative cash flows without product sales revenue, consistent with its clinical-stage biotech profile. The company will require additional capital to advance TA-ERT development, conduct trials, pursue commercialization, and cover public company costs. Prior and expected future net losses continue adversely affecting stockholders' equity and working capital, highlighting the need for sustained financing to extend runway and execute strategic priorities.